BOSTON and LONDON, September 17, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced …
[Read more...] about Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Akari Therapeutics Reports Second Quarter – 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s …
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic …
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
• Interim CEO employment contract consists solely of equity compensation • Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m …
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
BOSTON and LONDON – June 4, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for …
[Read more...] about Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
